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Evaluation of Propofol Usage and Selected
Adverse Events in Adult Patients
Medication Use Evaluation Results
Background: Propofol has a
rapid onset and short duration of
action once discontinued; therefore, it is often used to provide
sedation for patients in whom
frequent neurologic evaluations
may be necessary. Although propofol is a highly effective sedative agent, it has been associated
with many adverse effects.1,2
Adverse effects commonly associated with propofol include hypotension, which is usually doserelated and occurs more frequently following bolus administration, bradycardia, and pain
upon injection. In addition, rare
cases of metabolic acidosis,
rhabdomyolysis, hyperkalemia,
and/or cardiac failure have been
reported.1,2
Propofol is manufactured as a
phospholipid emulsion that has
the potential to cause hypertriglyceridemia and subsequent
pancreatitis when high doses are
used or when it is used for prolonged periods of time. Patients
at risk of hyperlipidemia should
be monitored for increases in
serum triglycerides as well
as elevations in pancreatic
enzymes.

Propofol requires a dedicated
infusion catheter when administered as a continuous infusion because of the potential for drug incompatibilities and line infections.
The manufacturer suggests that
the propofol infusion bottle and
tubing should not hang for longer
than 12 hours.1,2
Purpose: The purpose of this
medication use evaluation (MUE)
was to assess propofol usage and
selected adverse events in adult
patients.
Methods: Patients were identified
for review based on records from
the automated medication dispensing system (AcuDose-Rx®) or the
pharmacy order entry system
(MSMeds™) from August 2004 to
April 2005.
Patients were eligible for inclusion if they were at least 18 years
of age and received propofol during their hospitalization. In addition to patient demographics, the
following data were obtained: admitting diagnosis, attending and
prescribing physicians, service,
location, indication, dose, administration method, pharmacist order
review status, and adverse events.
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The adverse events included pain
on injection, bradycardia (ie, heart
rate less than 60 beats per minute),
hypotension (ie, systolic blood
pressure less than 90 mmHg or a
mean arterial pressure less than
60 mmHg), hypertriglyceridemia
(ie, triglycerides greater than
200 mg/dL), elevations in amylase
and lipase concentrations (ie, concentrations greater than 130 and
50 IU/L, respectively), and metabolic acidosis (ie, pH less than or
equal to 7.25, arterial HCO3 less
than 19 mEq/L, anion gap greater
than 12). Concomitant analgesic
medications and documentation of
propofol infusion bottle or tubing
changes were also recorded.
Results: There were 124 patients
and 137 records included in the
data analysis. Of these patients,
63 (46%) were male, 73 (53%)
were female, sex was unknown
for 1 (1%) patient. The average
age of the patients was 57 years
(range 15 to 90 years). The average patient weight was 82 kg
(range 44 to 171 kg).
A written order for propofol was
documented in the chart 85%
(n = 116) of the time and an order
was present in MSMeds™ 88%
(n = 121) of the time. Orders for
propofol were not documented in
the chart 15% (n = 21) of the time
and orders were not found in
MSMeds™ 12% (n = 16) of the
time. The absence of these records
may indicate emergent administration of propofol, transfer of the
patient from the operating room to
another unit, or lack of documentation. The formulary restriction
for propofol use was followed in
96% (n = 131) of the orders documented.

Propofol was ordered for the
following indications: continuous sedation (n = 92, 67%); continuous sedation during surgery
or a procedure (n = 14, 10%);
surgery (n = 16, 12%); and procedure (n = 7, 5%). The indication for propofol use was not
documented for 5 (6%) encounters.
One hundred nineteen
(87%) patients received propofol
via continuous infusion, compared with 13 (9%) patients receiving intravenous push.
The average initial continuous
infusion rate was 38 mcg/kg/min
(range 9 to 150 mcg/kg/min),
which is higher than the initial
rate (5 mcg/kg/min) recommended by the manufacturer for
initial ICU sedation and the
clinical practice guidelines by
the Society of Critical Care
Medicine.1,2 The infusions continued for an average of 2.8 days
(range 1 to 17 days). The minimum average daily rate for continuous infusion was 33 mcg/kg/
min (range 0.85 to 150 mcg/kg/
min), while the maximum average
daily
rate
was
49 mcg/kg/min (range 4.9 to
168 mcg/kg/min). These average daily rates are consistent
with those reported in the product labeling (5 to 50 mcg/kg/
min). Three patients had an
average maximum daily dose
that exceeded the dose recommended in the MUSC Continuous
Infusion
Guidelines
for Adult Patients (ie, 5 to
100 mcg/kg/min).
The
average
intravenous
push dose administered was
1.53 mg/kg (range 0.0027 to
2.4 mg/kg) and patients received

1.8 doses on average. The average dose is consistent with the
doses recommended for induction
of general anesthesia (ie, 0.5 to
2 mg/kg). The average total dose
given via intravenous push was
1.7 mg/kg (range 0.0027 to
3.6 mg/kg).
Adverse events that were evaluated are listed in Table 1. For the
13 patients who received propofol
via intravenous push, pain on injection was monitored for and
subsequently documented in 1 patient. Blood pressure was monitored in 12 (92.3%) patients, and 3
(23%) patients experienced hypotension. Systolic and diastolic
blood pressures decreased from
baseline by an average of 24%
and 30%, respectively (range, 14
to 35%, 17 to 43%, respectively).
Heart rate was monitored in 12
(92.3%) patients, and bradycardia
occurred in 1 (8%) patient.
Metabolic acidosis was assessed
in 108 patients (79%), but only
occurred in 9 patients (6.5%). In
patients who received propofol via
continuous infusion for at least 72
hours (n = 35), triglycerides were
monitored in 12 (34%) patients,
and elevated triglycerides occurred in 6 patients. Amylase and
lipase concentrations were monitored in 10 (29%) patients who
received propofol for at least 72
hours, and elevations occurred in
2 patients. Propofol bottle and/or
tubing changes were recorded in
only 40 records (29%).
Conclusion: Propofol is being
used for appropriate indications in
adult patients. The initial doses
used for continuous infusion and
the documented adverse events
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Table 1. Monitoring for and Occurrence of Selected Adverse Events

Bradycardia

Monitoring
Documented
n (%)
12 (92)

Occurrence
Documented
n (%)
1 (8)

Hypotension*

12 (92)

3 (23)

1 (8)

0 (0)

10 (29)

2 (20)

Hypertriglyceridema

12 (34)

6 (50)

Metabolic acidosis

108 (79)

9 (8)

*

Pain on injection*
Amylase and lipase elevations†
†

*
†

Monitored only in patients receiving propofol via intravenous push (n = 13)
Monitored only in patients receiving propofol via continuousinfusion for at least
72 hours (n = 35)

are higher than those reported in
the literature. Practitioners should
be educated regarding appropriate
dosing, duration of therapy, monitoring parameters, and adverse
events.
Process Improvements: Inservices will be provided to the professional staff regarding propofol
use and appropriate monitoring
parameters. A standardized propofol initiation order form will be
developed with weight-based dosing, titration guidelines, pertinent
monitoring parameters. An entry
will be placed on the medication
administration record to enhance
documentation of propofol infusion bottle and tubing changes.
MUE Team: This MUE was
conducted by Brent Anderegg,
Courtney Bickford, Wendy Bulllington, Brandy Causey, Anne
McDonnnell, Nicole Weimert,
Cathy Worrall, Nannette
Berensen, and Holly MacFall, and
Kelli Davis.
References and supporting documentation for this MUE are available upon request.

MED•U•WAY
Conference to Focus
on Moderate Sedation
The next MED•U•WAY
conference will focus on
moderate sedation and the best
practices to ensure patient safety.
The program will be held on
Thursday, February 16, 2006,
at 12:00 PM, in 2 West
Ampitheater.
The featured speakers will be
Gary Haynes MD, PhD, Department of Anesthesia and Perioperative Medicine, Marc Lapointe, PharmD, BCPS, BCNSP,
Associate Professor, Department
of Pharmacy and Clinical Sciences, and Phyllis Malpas, RN,
MA, GCRN, Manager Endoscopy.
The objectives are as follows:
• Define

moderate sedation
and the best practice initiatives that promote patient
safety.

• Identify and manage patients

who extend beyond the moderate level of sedation.

• Describe the what, how, and

why of reporting sedation
related adverse events.
Attendees will receive 1 credit
hour of continuing education and
lunch is provided. MED•U•WAY
is sponsored by the Pharmacy and
Therapeutics Committee.

Use of Prohibited
Abbreviations
By:
Amy Bain, PharmD Candidate
Medication errors significantly
affect iatrogenic morbidity and
mortality and increase healthcare
costs.1,2 In a case control study by
Classen and colleagues, medication errors were shown to increase
length of hospital stay by up to 5
days compared with matched controls.2 Costs related to medication
errors, in a large health system,
could be driven into the millions
based on the estimated $6,000 increased cost per error per hospital
stay.1 Many commonly encountered errors are a result of unsafe
prescribing practices, and about
11% of these are a result of the
use of dangerous abbreviations.1
Current institutional policies targeted to meet the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) accreditation standards prohibit the
use of dangerous abbreviations in
handwritten documentation.2 The
purpose of this regulation is to
reduce preventable prescribing
errors in order to improve patient
safety. The policy applies to all
types of handwritten documentation including orders, medicationrelated documentation in the
medical record, and preprinted
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order forms. The exceptions to
this policy include laboratory results or reports and vendor computed generated documents (ie,
medication administration record
[MAR]).
The MUSC-MC policy C-21 entitled Use of Abbreviations is summarized below.

• If a prohibited abbreviation is

• The list of Prohibited Abbre-

used in any other section of
the medical record, the author
should be contacted as soon
as possible and the information should be rewritten.

viations will be reviewed annually or at the discretion of the
Medical Director and/or the
Medical Records Committee.

abbreviation use
will be monitored via record
review, and trends that are
identified will be reported to a
department director or chair,
as necessary.

• No

abbreviations found on
the list of Prohibited Abbreviations may be used when documenting in the patient's inpatient or outpatient medical record (Table 2).

• Names of medications should

never be abbreviated (eg,
AZT, HCTZ, Neo).
• Abbreviations are not allowed

• Practitioners should be imme-

diately contacted via pager
upon discovery of use of a prohibited abbreviation in the orders section of the medical record, and the order should be
rewritten.

Reduction of medication errors is
ultimately dependent on the commitment of individual healthcare
professionals to observe the
MUSC-MC policies regarding
safe medication practices. Avoiding the use of dangerous abbreviations enables all practitioners and
hospital staff to contribute to the
improvement of patient safety.

• Prohibited

Policies regarding the use of abbreviations and other policies related to patient safety may be
found at musc.edu/medcenter/
policy/Med/clintoc.html.

in an informed consent document or when documenting
final diagnoses.
• Any request to change this list

may be submitted to the
Medical Records Committee.

References are available upon request.

Table 2. Prohibited Abbreviations Based on MUSC-MC Policy C-21
Prohibited
Abbreviation
Absence of a
preceding zero (.5 mg)

Intended Meaning

Misinterpretation

0.5 mg

The decimal point may not be seen or copied, resulting
in a 10-fold overdose.

Presence of a
trailing zero (5.0 mg)

5 mg

The decimal point may not be seen or copied, resulting
in a 10-fold overdose.

µg, mcg, or ug

microgram

This may be mistaken for “mg” when handwritten and
may result in an overdose.

qd, q.d., or QD

every day

The period after the “q” has been mistaken for “I,”
and the medication is administered “QID” (4 times
daily) rather than daily.

qod, q.o.d, or QOD

every other day

This may be mistaken as “q.d.” or “q.i.d” if the “o” is
poorly written.

MS, MSO4

morphine sulfate

This may be mistaken for magnesium sulfate.

MgSO4

magnesium sulfate

U or u

unit or umbilicus

This may be mistaken as a 0 or 4, resulting in overdose
(4U seen as “40” or 4u seen as “44”).

IU

international unit

This may be misread as IV (intravenous).

This may be mistaken for morphine sulfate.

